2019 Q1 Form 10-Q Financial Statement
#000156459019017568 Filed on May 09, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $0.00 | $481.0K |
| YoY Change | -100.0% | 2431.58% |
| Cost Of Revenue | $0.00 | $430.0K |
| YoY Change | -100.0% | 2050.0% |
| Gross Profit | $0.00 | $51.00K |
| YoY Change | -100.0% | |
| Gross Profit Margin | 10.6% | |
| Selling, General & Admin | $12.71M | $6.070M |
| YoY Change | 109.34% | 589.77% |
| % of Gross Profit | 11901.96% | |
| Research & Development | $9.730M | $7.620M |
| YoY Change | 27.69% | 186.47% |
| % of Gross Profit | 14941.18% | |
| Depreciation & Amortization | $100.0K | $200.0K |
| YoY Change | -50.0% | |
| % of Gross Profit | 392.16% | |
| Operating Expenses | $22.43M | $13.69M |
| YoY Change | 63.85% | 286.86% |
| Operating Profit | -$22.43M | -$13.64M |
| YoY Change | 64.46% | 285.53% |
| Interest Expense | $1.010M | $260.0K |
| YoY Change | 288.46% | 116.67% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$20.00K | |
| YoY Change | ||
| Pretax Income | -$21.44M | -$13.38M |
| YoY Change | 60.24% | 291.23% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$21.44M | -$13.38M |
| YoY Change | 60.25% | 291.63% |
| Net Earnings / Revenue | -2782.12% | |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.109M | -$876.2K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 20.48M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $246.7M | $127.5M |
| YoY Change | 93.49% | |
| Cash & Equivalents | $246.7M | $127.5M |
| Short-Term Investments | $0.00 | |
| Other Short-Term Assets | $1.600M | $900.0K |
| YoY Change | 77.78% | |
| Inventory | $300.0K | |
| Prepaid Expenses | ||
| Receivables | $0.00 | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $248.3M | $128.7M |
| YoY Change | 92.93% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $929.0K | $600.0K |
| YoY Change | 54.83% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $2.777M | $0.00 |
| YoY Change | ||
| Total Long-Term Assets | $3.757M | $700.0K |
| YoY Change | 436.71% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $248.3M | $128.7M |
| Total Long-Term Assets | $3.757M | $700.0K |
| Total Assets | $252.1M | $129.4M |
| YoY Change | 94.79% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.700M | $4.000M |
| YoY Change | -57.5% | |
| Accrued Expenses | $8.600M | $1.300M |
| YoY Change | 561.54% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $10.28M | $5.500M |
| YoY Change | 86.85% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $2.200M | |
| YoY Change | ||
| Total Long-Term Liabilities | $2.184M | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $10.28M | $5.500M |
| Total Long-Term Liabilities | $2.184M | $0.00 |
| Total Liabilities | $12.46M | $5.500M |
| YoY Change | 126.56% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$144.3M | |
| YoY Change | ||
| Common Stock | $56.00K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $239.6M | $123.9M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $252.1M | $129.4M |
| YoY Change | 94.79% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$21.44M | -$13.38M |
| YoY Change | 60.25% | 291.63% |
| Depreciation, Depletion And Amortization | $100.0K | $200.0K |
| YoY Change | -50.0% | |
| Cash From Operating Activities | -$17.93M | -$9.624M |
| YoY Change | 86.35% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $44.00K | $72.00K |
| YoY Change | -38.89% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $35.90M |
| YoY Change | -100.0% | |
| Cash From Investing Activities | -$44.00K | $35.83M |
| YoY Change | -100.12% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $162.0M | $64.26M |
| YoY Change | 152.08% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 163.5M | 64.26M |
| YoY Change | 154.46% | |
| NET CHANGE | ||
| Cash From Operating Activities | -17.93M | -9.624M |
| Cash From Investing Activities | -44.00K | 35.83M |
| Cash From Financing Activities | 163.5M | 64.26M |
| Net Change In Cash | 145.5M | 90.46M |
| YoY Change | 60.87% | |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$17.93M | -$9.624M |
| Capital Expenditures | $44.00K | $72.00K |
| Free Cash Flow | -$17.98M | -$9.696M |
| YoY Change | 85.42% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
246692000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
101318000 | |
| CY2019Q1 | us-gaap |
Restricted Investments Current
RestrictedInvestmentsCurrent
|
407000 | |
| CY2018Q4 | us-gaap |
Restricted Investments Current
RestrictedInvestmentsCurrent
|
253000 | |
| CY2019Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1196000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
672000 | |
| CY2019Q1 | us-gaap |
Assets Current
AssetsCurrent
|
248295000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
102243000 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
929000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
948000 | |
| CY2019Q1 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
51000 | |
| CY2018Q4 | us-gaap |
Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
|
51000 | |
| CY2019Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2777000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
317000 | |
| CY2019Q1 | us-gaap |
Assets
Assets
|
252052000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
103559000 | |
| CY2019Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
5942000 | |
| CY2018Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
8540000 | |
| CY2019Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3334000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4925000 | |
| CY2019Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1001000 | |
| CY2019Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10277000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
13465000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2184000 | |
| CY2019Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
2184000 | |
| CY2019Q1 | us-gaap |
Liabilities
Liabilities
|
12461000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
13465000 | |
| CY2019Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
56000 | |
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
44000 | |
| CY2019Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
383850000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
212921000 | |
| CY2019Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-144315000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-122871000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
239591000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
90094000 | |
| CY2019Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
252052000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
103559000 | |
| CY2019Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
20758348 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
16214883 | |
| CY2019Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
20758348 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
16214883 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
481000 | |
| CY2018Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
430000 | |
| CY2018Q1 | us-gaap |
Gross Profit
GrossProfit
|
51000 | |
| CY2019Q1 | urgn |
Research And Development Expense Net
ResearchAndDevelopmentExpenseNet
|
9726000 | |
| CY2018Q1 | urgn |
Research And Development Expense Net
ResearchAndDevelopmentExpenseNet
|
7622000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12707000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6069000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-22433000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13640000 | |
| CY2019Q1 | urgn |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
989000 | |
| CY2018Q1 | urgn |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
258000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21444000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13382000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
1.11 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.88 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19340082 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
15267939 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2047000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7447000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
161447000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68515000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4541000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
64193000 | |
| CY2018Q1 | us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
-35901000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
44000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
72000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-44000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
35829000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
123867000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
63000 | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
240000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7447000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4541000 | |
| CY2018Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-1000 | |
| CY2018Q1 | us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
-100000 | |
| CY2019Q1 | urgn |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
245000 | |
| CY2019Q1 | urgn |
Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
|
173000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
33000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
41000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-232000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2440000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-206000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-454000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1591000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-659000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17934000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9624000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1532000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
161974000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
64256000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
163506000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
64256000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
145528000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
90461000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
101571000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
36999000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
247099000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
127460000 | |
| CY2019Q1 | urgn |
Noncash Issuance Cost
NoncashIssuanceCost
|
312000 | |
| CY2018Q1 | urgn |
Noncash Issuance Cost
NoncashIssuanceCost
|
21000 | |
| CY2019Q1 | urgn |
Non Cash Exercise Of Stock Options
NonCashExerciseOfStockOptions
|
515000 | |
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTE_1BUSINESS_NATURE_OPERATIONS"></a><a name="NOTE_1BUSINESS_NATURE_OPERATIONS"></a>NOTE 1-BUSINESS AND NATURE OF OPERATIONS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Ltd.<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>20<font style="letter-spacing:-0.1pt;">0</font>4<font style="letter-spacing:0.45pt;"> </font>(“UPL”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Inc.,<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>UPL,<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Del<font style="letter-spacing:-0.1pt;">a</font>ware<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2015<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>began<font style="letter-spacing:0.5pt;"> </font>operati<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>(“UPI”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>(together<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>“Company”)<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>clinical<font style="letter-spacing:0.55pt;"> </font>stage<font style="letter-spacing:0.45pt;"> </font>bi<font style="letter-spacing:-0.1pt;">o</font>pharmaceutical<font style="letter-spacing:1.45pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>focused<font style="letter-spacing:0.65pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>oping<font style="letter-spacing:0.85pt;"> </font>novel<font style="letter-spacing:0.45pt;"> </font>therapies<font style="letter-spacing:0.75pt;"> </font>desi<font style="letter-spacing:-0.1pt;">g</font>ned<font style="letter-spacing:0.75pt;"> </font>to change<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>care<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>urological<font style="letter-spacing:0.8pt;"> </font>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, preparing for the potential commercial launch of its lead product candidates, UGN-101 and UGN-102, and raising capital to support and expand these activities.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p> | |
| CY2019Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2-BASIS OF PRESENTATION</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated financial statements include the accounts of UPL and its wholly-owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly-owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and has an accumulated deficit of $144.3 million and $122.9 million as of March 31, 2019 and December 31, 2018, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it expands its portfolio and engages in further research and development activities, particularly conducting preclinical studies and clinical trials.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on its ability to develop its technologies to the point of U.S. Food and Drug Administration (<font style="color:#000000;">“</font>FDA<font style="color:#000000;">”</font>) approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these efforts. Based on our cash flow projections, we believe that our current cash and cash equivalents are sufficient to fund our business plans for at least the next 12 months. However, in the future, management may need to raise additional capital to finance the continued operating and capital requirements of the Company. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. If the Company cannot obtain adequate working capital, it may be forced to reevaluate its planned business operations.</p> | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>preparation<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>conformity<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>GAAP<font style="letter-spacing:0.5pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>man<font style="letter-spacing:-0.1pt;">a</font>gement<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>affect the<font style="letter-spacing:0.05pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>disclosure<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cont<font style="letter-spacing:-0.1pt;">i</font>ngent<font style="letter-spacing:0.85pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financ<font style="letter-spacing:-0.1pt;">i</font>al<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>duri<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>Actual<font style="letter-spacing:0.5pt;"> </font>results<font style="letter-spacing:0.55pt;"> </font>may<font style="letter-spacing:0.35pt;"> </font>differ<font style="letter-spacing:0.45pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>estimates.<font style="letter-spacing:0.8pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>applicable<font style="letter-spacing:0.9pt;"> </font>to the unaudited condensed<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financi<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.65pt;"> </font>statements,<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>most<font style="letter-spacing:0.4pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>relate<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on, the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>timing<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition.</p> | |
| CY2019Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<font style="color:#000000;">’</font>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<font style="color:#000000;">’</font>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term investments. The Company deposits cash and cash equivalents with highly rated financial institutions, has not experienced any credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</p> | |
| CY2019Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2004-04-30 | |
| CY2019Q1 | us-gaap |
Operations Commenced Date1
OperationsCommencedDate1
|
2016-02-29 | |
| CY2019Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1700000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4272000 | |
| CY2019Q1 | urgn |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
839000 | |
| CY2018Q4 | urgn |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
673000 | |
| CY2019Q1 | urgn |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
1396000 | |
| CY2018Q4 | urgn |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
780000 | |
| CY2019Q1 | urgn |
Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
|
1298000 | |
| CY2018Q4 | urgn |
Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
|
1029000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
709000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1786000 | |
| CY2019Q1 | urgn |
Interest Income Expenses On Cash And Cash Equivalents
InterestIncomeExpensesOnCashAndCashEquivalents
|
1010000 | |
| CY2018Q1 | urgn |
Interest Income Expenses On Cash And Cash Equivalents
InterestIncomeExpensesOnCashAndCashEquivalents
|
422000 | |
| CY2019Q1 | urgn |
Other Finance Expenses Income
OtherFinanceExpensesIncome
|
-21000 | |
| CY2018Q1 | urgn |
Other Finance Expenses Income
OtherFinanceExpensesIncome
|
-64000 | |
| CY2019Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1733000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1695000 | |
| CY2019Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
804000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
747000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
100000 | |
| CY2018Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
200000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
In order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P3Y | |
| CY2019Q1 | urgn |
Lessee Operating Lease Extended Lease Expiration Date Month And Year
LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear
|
2022-08 | |
| CY2019Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
3022000 | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y3M29D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0724 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
886000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1220000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
649000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
492000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
301000 | |
| CY2019Q1 | urgn |
Lessee Operating Lease Liability Payments Due Year Six And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter
|
58000 | |
| CY2019Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
302000 | |
| CY2019Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
30000 | |
| CY2019Q1 | us-gaap |
Lease Cost
LeaseCost
|
332000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3022000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2777000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2429000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
929000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1001000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2019Q1 | us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
0 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
256000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
3606000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
421000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3185000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1136000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1251000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
676000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
567000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
301000 | |
| CY2018Q4 | urgn |
Operating Leases Future Minimum Payments Due In Six Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter
|
58000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
3989000 | |
| CY2018 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
1200000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P1Y | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7447000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4541000 | |
| CY2019Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
63200000 | |
| CY2019Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y4M24D |
